Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Nov 28, 2020; 26(44): 7022-7035
Published online Nov 28, 2020. doi: 10.3748/wjg.v26.i44.7022
Table 3 Comparison of the changes in the carcinoembryonic antigen level before and after chemoradiotherapy
VariablesGroup A (n = 27)Group B (n = 43)Group C (n = 65)P value
Age, yr> 0.999
< 6517 (63.0%)27 (62.8%)41 (63.1%)
≥ 6510 (37.0%)16 (37.2%)24 (36.9%)
Sex0.358
Male21 (77.8%)34 (79.1%)44 (67.7%)
Female6 (22.2%)9 (20.9%)21 (32.3%)
ASA0.734
< 323 (85.2%)38 (88.4%)59 (90.8%)
≥ 34 (14.8%)5 (11.6%)6 (9.2%)
Pre-CRT tumor size (cm)4.6 (3.7-5.0)4.5 (4.0-5.1)4.3 (3.8-5.0)0.515
Pre-CRT CEA (ng/mL)25.8 (10.6-70.7)11.3 (6.8-21.3)2.4 (1.8-3.3)< 0.001
Pre-CRT NLR0.983
< 2.817 (63.0%)28 (65.1%)42 (64.6%)
≥ 2.810 (37.0%)15 (34.9%)23 (35.4%)
Pre-CRT PLR0.132
< 138.211 (40.7%)19 (44.2%)39 (60.0%)
≥ 138.216 (59.3%)24 (55.8%)26 (40.0%)
Pre-CRT T stage0.217
T318 (66.7%)34 (79.1%)54 (83.1%)
T49 (33.3%)9 (20.9%)11 (16.9%)
Pre-CRT N stage0.021
N01 (3.7%)1 (2.3%)11 (16.9%)
N+26 (96.3%)42 (97.7%)54 (83.1%)
Pre-CRT TNM stage0.021
I1 (3.7%)00
II1 (3.7%)1 (2.3%)11 (16.9%)
III25 (92.6%)42 (97.7%)54 (83.1%)
Post-CRT CEA (ng/dL)8.4 (6.0–13.7)2.9 (2.0–4.0)1.8 (1.2–2.9)< 0.001
Post-CRT T stage0.001
0–23 (11.1%)5 (11.6%)25 (38.5%)
3–424 (88.9%)38 (88.4%)40 (61.5%)
Post-CRT N stage0.006
N08 (29.6%)20 (46.5%)42 (64.6%)
N+19 (70.4%)23 (53.5%)23 (35.4%)
Post-CRT M stage0.090
025 (92.6%)42 (97.7%)65 (100%)
12 (7.4%)1 (2.3%)0
Post-CRT TNM Stage0.008
0002 (3.1%)
I2 (7.4%)4 (9.3%)19 (29.2%)
II5 (18.5%)15 (34.9%)21 (32.3%)
III19 (66.7%)23 (53.5%)23 (35.4%)
IV2 (7.4%)1 (2.3%)0
Down-staging on MRI after CRT0.013
No21 (77.8%)25 (58.1%)29 (44.6%)
Yes6 (22.2%)18 (41.9%)36 (55.4%)